June 24, 2026
Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally
June 24, 2026 - The Alliance for Clinical Trials in Oncology has launched a new national study to see if an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Alliance A082302 aims to enroll 336 participants in this phase III trial specifically focusing on patients with stage I non-small cell lung cancer.
Currently, after an early-stage lung tumor is successfully remov
June 22, 2026 - The Alliance for Clinical Trials in Oncology has honored Electra Paskett, PhD, FACE, FAACR, FASCO, as the 2026 Charles G. Moertel Lecturer.
Dr. Paskett is the Marion N. Rowley Professor of Cancer Research and Director at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, as well as the Director and Principal Investigator of the Alliance Cancer Control Program.
As a pre
